An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

doi:10.1111/hae.13222

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	e444-e447
Journal	Haemophilia
Volume	23
Issue number	5
DOIs	https://doi.org/10.1111/hae.13222
State	Published - Sep 2017

Access to Document

10.1111/hae.13222

Cite this

@article{d6cdc6cee40e4c64a4775c2c6ea206e2,

title = "An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia",

author = "\{the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators\} and Carcao, \{M. D.\} and L. Avila and C. Leissinger and Blanchette, \{V. S.\} and L. Aledort",

note = "Funding Information: We wish to thank all those who contributed data for this survey as well as the staff at the coordinating center (Audrey Abad, Dan Ignas and Nicole Rivera) and the funders of the IPSG: Baxalta (now a part of Shire); Bayer Healthcare; Biogen Idec; CSL Behring; Novo Nordisk Healthcare AG and Pfizer. Funding for the IPSG is provided through grants administered by The Hospital for Sick Children Foundation, Toronto, Canada.",

year = "2017",

month = sep,

doi = "10.1111/hae.13222",

language = "English",

volume = "23",

pages = "e444--e447",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia. / the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators.
In: Haemophilia, Vol. 23, No. 5, 09.2017, p. e444-e447.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - An International Prophylaxis Study Group (IPSG) survey of prophylaxis in inhibitor positive children/adults with severe haemophilia

AU - the Factor Utilization Expert Working Group of the International Prophylaxis Study Group (IPSG) and Participating Survey Investigators

AU - Carcao, M. D.

AU - Avila, L.

AU - Leissinger, C.

AU - Blanchette, V. S.

AU - Aledort, L.

N1 - Funding Information: We wish to thank all those who contributed data for this survey as well as the staff at the coordinating center (Audrey Abad, Dan Ignas and Nicole Rivera) and the funders of the IPSG: Baxalta (now a part of Shire); Bayer Healthcare; Biogen Idec; CSL Behring; Novo Nordisk Healthcare AG and Pfizer. Funding for the IPSG is provided through grants administered by The Hospital for Sick Children Foundation, Toronto, Canada.

PY - 2017/9

Y1 - 2017/9

UR - https://www.scopus.com/pages/publications/85018699143

U2 - 10.1111/hae.13222

DO - 10.1111/hae.13222

M3 - Letter

C2 - 28439934

AN - SCOPUS:85018699143

SN - 1351-8216

VL - 23

SP - e444-e447

JO - Haemophilia

JF - Haemophilia

IS - 5

ER -